Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

Phase 1

Completed

Conditions: Sciatica

Interventions: Drug: Placebo
Drug: CEP-37247

Registration Number: NCT01240876

Lead Sponsor: Cephalon

Brief Summary: The primary objective of the study is to evaluate the safety and efficacy of CEP-37247 compared with placebo as assessed by the occurrence of adverse events, and the mean change in average pain intensity (API) in the affected leg.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 98

Inclusion Criteria

Over the 4 days prior to the randomization visit, the patient has a mean score greater than or equal to 5 (of 10) for "Average Pain Over the Past 24 Hours" for the pain in the affected leg as assessed by the 11-Point Numerical Rating Scale (NRS-11) captured in the electronic diaries. The patient must have valid (non-missing) data for at least 3 out of the 4 days, and the mean score must be at least 5 without rounding.
The patient has a current diagnosis of lumbosacral radicular pain. Pain must radiate into the leg in a dermatomal/myotomal distribution consistent with the diagnosis of lumbosacral radicular pain in the suspected involved nerve root. Based on history and medical records (if available), the duration of the current episode of pain must be between 6 and 52 weeks duration.
Diagnosis must be confirmed by magnetic resonance imaging (MRI) (or existing computed tomography [CT] or MRI related to the symptoms present at screening) performed within 6 months prior to screening and demonstrating disk herniation at a location consistent with the clinical symptoms of radicular pain. Other incidental pathology is permitted as long as it is asymptomatic and believed not causal of the primary diagnosis of lumbosacral radicular pain at the specific spinal level as described below.
The patient must have at least 1 of the following: a positive straight leg raise (L5-S1), positive femoral stretch test (L3-L4), or other positive test result upon physical examination that is consistent with the presence of nerve root irritation at the nerve root suspected to be involved in the diagnosed lumbosacral radicular pain at screening.
Herniation must affect L3-L4, L4-L5, or L5-S1 and must be consistent with clinical presentation of the current episode of lumbosacral radicular pain as described above.
Patients with significant or progressive sensory impairment or motor impairment (such as foot drop) must be assessed on a case-by-case basis by the investigator, and must in each case receive written approval of the Sponsor prior to randomization.
There must be confirmation that the patient does not have an active tuberculosis infection at screening. The patient should have either a negative QuantiFERON®-TB Gold blood test or negative tuberculin skin test (TST) result at screening; however if QuantiFERON®-TB Gold test or TST is positive, a chest radiogram may be used to determine whether a patient has an active infection.
The patient is willing to keep all analgesic medication and other therapy usage (such as physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation [TENS]) stable or decreased during the study and use only the rescue pain medication as needed and as specified by the protocol.
The patient is in good health (with the exception of the condition under study) as determined by a medical and psychiatric history, medical examination, ECG, serum chemistry, hematology, urinalysis, and serology.
Women of childbearing potential (ie, not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening.

Exclusion Criteria

The patient:

has a documented history of an allergic reaction (hives, rash, etc.) or a clinically significant intolerance to study drug or ingredients.
has a body mass index (BMI) greater than 40 kg/m2.
the patient has an established history of a major psychiatric disorder, not controlled with medication or appears to have anxiety that would interfere with clinical pain scores or participation in the trial.
has clinically significant abnormalities in clinical chemistry, hematology or urinalysis, including serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (AST) or serum glutamic-pyruvic transaminase/alanine aminotransferase (ALT) greater than or equal to 3 times the upper limit of the reference range or an estimated glomerular filtration rate (eGFR) less than or equal to 30 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD] study formula) at screening.
has received an intra-epidural steroid injection for the treatment of the current episode of sciatica during the last 3 months prior to screening.
has significant pain unrelated to the disk herniation that would significantly compromise assessment of the radicular back and leg pain related to the disk herniation.
has radiologic evidence of disk herniation at more than 1 spinal level, and clinical evidence of lumbosacral radicular pain at more than 1 spinal nerve corresponding to the levels of the multiple disk herniations.
has received any investigational drug within 30 days prior to screening, or is scheduled to receive an investigational drug other than blinded study drug during the course of this study.
has had lumbar or sacral back surgery related to the specific disk that is the cause of the radicular pain upon presentation to the study, or currently plans to undergo spine surgical intervention while in the study.
has received epidural corticosteroid injections in the back within 3 months of screening.
is involved in an ongoing worker's compensation claim, disability claim, or litigation related to any pain problem.
has any active infection that is not self-limiting and not resolved prior to study drug administration.
has a history of malignancy or evidence of malignancy or lymphoproliferative or neoplastic disease with the exception of successfully treated basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia within 5 years of the screening visit.
has a history of systemic fungal infection.
has a history of opportunistic infection within 3 months prior to screening.
has a history of known or suspected chronic infection, tuberculosis, hepatitis B virus (HBV), hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV). The investigator will review all medical history (including medication history), and patients found to be HIV positive based on medical review are to be excluded from the study.
has a history of any demyelinating disease, including multiple sclerosis and optic neuritis.
has used anti-tumor necrosis factor (TNF) receptor medication (anakinra [KINERET®, Biovitrum]) or anti-TNF medication (etanercept [ENBREL®, Amgen Inc.], infliximab [REMICADE®, Centocor Ortho Biotech Inc.], or adalimumab [HUMIRA®, Abbott Laboratories], or any experimental TNF inhibitor) within the past year.
has a planned joint replacement surgery or a history of infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.
has been given live vaccines within 14 days of study drug administration.
has severe spinal stenosis or spondylolisthesis (grade 2 or higher).
has coagulopathy.
is a pregnant or lactating woman (any women becoming pregnant during the study will be withdrawn from the study).
has a history of diabetic neuropathy or peripheral neuropathy in the lower extremities.
has a history of any condition (not otherwise specified) known to be amenable to TNF inhibitors (e.g., Crohn's disease).
has a known allergy or idiosyncratic (atopic) reaction to contrast agent, local anesthetic, study drug, any ingredient listed as being present in a study formulation, or any other pain management compound likely to be prescribed in the study, including their metabolites (if applicable) or any ingredient listed as being present in their formulations.
has any clinically significant uncontrolled medical condition (treated or untreated).

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Matching placebo	Placebo	-
CEP-37247	CEP-37247	-

Primary Outcome Measures

Name	Time	Method
Occurrence of adverse events compared to placebo	throughout the 28-week double-blind treatment period
Mean change in the weekly average of daily average pain intensity (API) in the affected leg on the 11-Point Numerical Rating Scale (NRS-11)	at week 4 compared with baseline	The average pain intensity over the past 24 hours on the NRS-11 will be collected daily by electronic diary.

Secondary Outcome Measures

Name	Time	Method
Evaluate the safety of CEP-37247 treatment as assessed by neurologic examination	at weeks 1, 2, 4 and 28 (or early termination)
Weekly average of daily worst back pain score as assessed by the NRS-11 from electronic diary entries	at each of the first 6 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Evaluate the safety of CEP-37247 treatment as assessed by physical examination	at weeks 4 and 28 (or early termination)
Evaluate the safety of CEP-37247 treatment as assessed by concomitant medication usage	throughout the 28-week double-blind treatment period
Characterize the serum pharmacokinetics of CEP-37247 following epidural administration	Throughout the 28-week double-blind treatment period
Weekly average of daily back API score as assessed by the NRS-11 from electronic diary entries	at each of the first 6 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Patients with 30% and 50% reductions in average pain over the previous 24 hours as measured by the Brief Pain Inventory Short Form (BPI-SF)	at 1, 2, 4, 6, 14, and 28 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Average daily amount of rescue medication used	during each of the first 6 weeks of the 28-week double-blind treatment period	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Evaluate the safety of CEP-37247 treatment as assessed by clinical laboratory tests	at weeks 1, 2, 4, 6, 14, and 28 (or early termination)
Change in total Oswestry Disability Index (ODI) score as well as subscale scores	at 1, 2, 4, 6, 14, and 28 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Score on the Patient Global Impression of Change	at 1, 2, 4, 6, 14, and 28 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Change in 36-Item Short Form Health Survey (SF-36) score	from baseline to weeks 4, 14, and 28	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Patients requiring a subsequent injection of epidural steroids	up to 28 weeks after CEP-37247 treatment	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Patients requiring back surgery	up to 28 weeks after CEP-37247 treatment	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Evaluate the safety of CEP-37247 treatment as assessed by immunogenicity tests	at weeks 2, 4, 6, 14, and 28 (or early termination)
Weekly average of daily leg API score as assessed by the NRS-11 from electronic diary entries	at each of the first 6 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Weekly average of daily worst leg pain score as assessed by the NRS-11 from electronic diary entries	at each of the first 6 weeks	Evaluate the efficacy of each dose of CEP-37247 as compared with placebo within each individual dose group and with the combined placebo group.
Evaluate the safety of CEP-37247 treatment as assessed by vital signs measurements	at weeks 1, 2, 4, 6, 14, and 28 (or early termination)
Evaluate the safety of CEP-37247 treatment as assessed by electrocardiogram (ECG) results	at week 4

Trial Locations

Locations (24): Teva Investigational Site 1
🇺🇸
Greenville, South Carolina, United States
Teva Investigational Site 17
🇺🇸
Altoona, Pennsylvania, United States
Teva Investigational Site 18
🇺🇸
Laguna Hills, California, United States
Teva Investigational Site 10
🇺🇸
Marietta, Georgia, United States
Teva Investigational Site 19
🇺🇸
Pasadena, California, United States
Teva Investigational Site 9
🇺🇸
Bloomington, Illinois, United States
Teva Investigational Site 16
🇺🇸
Dayton, Ohio, United States
Teva Investigational Site 4
🇺🇸
Orem, Utah, United States
Teva Investigational Site 5
🇺🇸
Sarasota, Florida, United States
Teva Investigational Site 102
🇦🇺
Malvern East, Australia
Teva Investigational Site 100
🇦🇺
North Terrace, Australia
Teva Investigational Site 13
🇺🇸
Marietta, Georgia, United States
Teva Investigational Site 22
🇺🇸
La Mesa, California, United States
Teva Investigational Site 15
🇺🇸
Overland Park, Kansas, United States
Teva Investigational Site 21
🇺🇸
Eugene, Oregon, United States
Teva Investigational Site 6
🇺🇸
Spartanburg, South Carolina, United States
Teva Investigational Site 103
🇦🇺
Caulfied South, Australia
Teva Investigational Site 3
🇺🇸
Salt Lake City, Utah, United States
Teva Investigational Site 2
🇺🇸
Pasadena, California, United States
Teva Investigational Site 8
🇺🇸
Shreveport, Louisiana, United States
Teva Investigational Site 11
🇺🇸
North Charleston, South Carolina, United States
Teva Investigational Site 101
🇦🇺
St. Leonards, Australia
Teva Investigational Site 14
🇺🇸
Orlando, Florida, United States
Teva Investigational Site 20
🇺🇸
Winston-Salem, North Carolina, United States